StockData
Neumora Therapeutics, Inc. logo

Neumora Therapeutics, Inc. (NMRA) stock

NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 2/30
$0.33−0.03 (-9.47%)

Close on Nov 17, 2026Market cap $62.85MP/E –Yield –

Neumora Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Neumora Therapeutics's free cash flow for the twelve months ending Dec 31, 2023 was -$163.40M. For fiscal 2023 it was -$163.40M.

Annual free cash flow

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$163.40M–
FY2022Dec 31, 2022-$115.41M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023-$51.49M–
Q3 FY2023Sep 30, 2023-$47.81M–
Q2 FY2023Jun 30, 2023-$31.02M–
Q1 FY2023Mar 31, 2023-$33.08M–
Q4 FY2022Dec 31, 2022-$30.39M–

More Neumora Therapeutics figures

See a number that looks wrong?